白芍总苷联合泼尼松治疗多发性肌炎的疗效分析

Clinical efficacy of total glucosides of paeony combined with prednisone in the treatment of polymyositis patients

目的观察白芍总苷(TGP)联合泼尼松治疗多发性肌炎(PM)的疗效和安全性。方法 25例PM患者纳入研究并随机分为两组,白芍总苷联合泼尼松治疗组(A组)14例,单用泼尼松治疗组(B组)11例。所有病例随访24周。随访过程监测肌酸肌酶(CK)、天冬酸氨基转移酶(AST)、乳酸脱氢酶(LDH)以及激素用量的变化。结果随访终点,两组的肌酶均较基线有明显下降(P<0.01)。但A组的CK、LDH下降更明显且更快(P<0.05)。A组平均激素累积量4 130 mg,明显低于B组的5 005 mg(P<0.01)。两组间的不良反应发生率无显著差异(P>0.05)。结论白芍总苷联合泼尼松治疗多发性肌炎疗效佳且安全性好。

Objective To evaluate the efficacy and safety of total glucosides of paeony （TGP） combined with pred- nisone in the treatment of polymyositis （PM） patients. Methods A total of 25 cases of PM were randomized to TGP plus prednisone combination therapy group （group A, n=14） and single prednisone therapy group （group B, n=l 1 ）. All cases had been follow-up for 24 weeks. The following parameters were observed at week 0,2,4,8,12,16,24： Creatine kinase （CK）, aspartate transaminase （AST）, lactate dehydrogenase （LDH） and the accumulated dose of pred- nisone. Results At the end point, the level of Creatases （CK,AST, and LDH） were all decreased significantly com- pared to study entry in both groups （P〈0.01）. The decrease of the level of CK and LDH were observed more signifi- cantly and quickly in group A compared to group B （P〈0.05）. The mean accumulated dose of prednisone was 4130 mg in group A, significant lower than the 5005 mg in group B （P〈0.01）. No significant difference of the incidence of ad- verse drug reaction was found between two groups （P〉0.05）. Conclusion TGP combine with prednisone shows good efficacy and safety in the treatment of PM patients.